{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:15:51Z","timestamp":1789917351718,"version":"4.0.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.pharmthera.2012.06.003","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T13:30:25Z","timestamp":1340717425000},"page":"1-7","source":"Crossref","is-referenced-by-count":42,"title":["Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin"],"prefix":"10.1016","volume":"136","author":[{"given":"Julien","family":"Hanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Gille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Offermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.06.003_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-5793(80)80715-0","article-title":"Nicotinic acid inhibits adipocyte adenylate cyclase in a hormone\u2010like manner","volume":"115","author":"Aktories","year":"1980","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0773.1977.tb02116.x","article-title":"Studies on the mechanism of flush induced by nicotinic acid","volume":"41","author":"Andersson","year":"1977","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(80)90058-6","article-title":"Blockade of chlorpropamide-alcohol flushing by indomethacin suggests an association between prostaglandins and diabetic vascular complications","volume":"2","author":"Barnett","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0002-8703(40)91029-8","article-title":"A study of the effects of nicotinic acid and related pyridine and pyrazine compounds on the temperature of the skin of human beings","volume":"20","author":"Bean","year":"1940","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells","volume":"70","author":"Beny\u00f3","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0040","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0045","doi-asserted-by":"crossref","first-page":"e20487","DOI":"10.1371\/journal.pone.0020487","article-title":"Nicotinic acid receptor abnormalities in human skin cancer: implications for a role in epidermal differentiation","volume":"6","author":"Bermudez","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1980.tb01788.x","article-title":"Time course changes in levels of arachidonic acid and prostaglandins D2, E2, F2 alpha in human skin following ultraviolet B irradiation","volume":"10","author":"Black","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0055","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0060","doi-asserted-by":"crossref","first-page":"11660","DOI":"10.1074\/jbc.274.17.11660","article-title":"Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2","volume":"274","author":"Brock","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0065","doi-asserted-by":"crossref","first-page":"58B","DOI":"10.1016\/j.amjcard.2008.02.039","article-title":"Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk","volume":"101","author":"Brown","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0070","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/19.5.723","article-title":"COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer","volume":"19","author":"Buckman","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0075","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00011-007-6167-6","article-title":"Potential role for epidermal Langerhans cells in nicotinic acid-induced vasodilatation in the mouse","volume":"56","author":"Carballo-Jane","year":"2007","journal-title":"Inflamm Res"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.hco.0000231404.76930.e9","article-title":"Nicotinic acid and other therapies for raising high-density lipoprotein","volume":"21","author":"Carlson","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0090","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.physiol.69.022405.154749","article-title":"Beta-arrestins and cell signaling","volume":"69","author":"DeWire","year":"2007","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MOL.0b013e32832d3b9d","article-title":"Nicotinic acid and the prevention of coronary artery disease","volume":"20","author":"Digby","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/0091270009332246","article-title":"Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms","volume":"49","author":"Dishy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0110","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1172\/JCI44098","article-title":"Seeing red: flushing out instigators of niacin-associated skin toxicity","volume":"120","author":"Dunbar","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0952-3278(93)90025-R","article-title":"Endogenous prostaglandin E2 modulates calcium-induced differentiation in human skin keratinocytes","volume":"49","author":"Evans","year":"1993","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.pa.36.040196.002405","article-title":"Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins","volume":"36","author":"Exton","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0125","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/jid.2010.416","article-title":"Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antipsoriatic effect?","volume":"131","author":"Garcia-Caballero","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0130","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1084\/jem.20100977","article-title":"Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells","volume":"208","author":"Ghoreschi","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0140","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00000441-194302000-00006","article-title":"The vasodilating effects of nicotinic acid: relation to metabolic rate and body temperature","volume":"205","author":"Goldsmith","year":"1943","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000063148","article-title":"Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris","volume":"205","author":"Gollnick","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0155","doi-asserted-by":"crossref","first-page":"252","DOI":"10.7326\/0003-4819-121-4-199408150-00003","article-title":"Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans","volume":"121","author":"Gray","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0160","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1073\/pnas.72.12.5130","article-title":"Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis","volume":"72","author":"Hammarstrom","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0165","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0170","first-page":"11","volume":"15","author":"Herrmann","year":"1964","journal-title":"Hautarzt"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2003.05433.x","article-title":"Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000017903","article-title":"Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis","volume":"196","author":"Hoxtermann","year":"1998","journal-title":"Dermatology"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A \u201chot\u201d topic in dyslipidemia management\u2014\u201chow to beat a flush\u201d: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0190","first-page":"114","article-title":"Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man","volume":"57","author":"Kaijser","year":"1979","journal-title":"Med Biol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0195","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.06.003_bb0200","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1038\/sj.bjp.0707604","article-title":"Agonist-selective mechanisms of GPCR desensitization","volume":"153","author":"Kelly","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0205","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0215","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacl.2008.08.445","article-title":"Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans","volume":"2","author":"Lai","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/excr.1996.0113","article-title":"Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation","volume":"224","author":"Leong","year":"1996","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0230","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0235","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.tips.2011.08.002","article-title":"Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials","volume":"32","author":"Lukasova","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0240","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI41651","article-title":"Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells","volume":"121","author":"Lukasova","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0245","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0250","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/jid.2011.46","article-title":"Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action","volume":"131","author":"Meissner","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb9000","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2012.01.045","volume":"59","author":"Michos","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0260","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molmed.2004.11.003","article-title":"Dimethylfumarate for psoriasis: more than a dietary curiosity","volume":"11","author":"Mrowietz","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0275","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1365-2133.1998.02124.x","article-title":"Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study","volume":"138","author":"Mrowietz","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0280","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0702866","article-title":"Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation","volume":"128","author":"Nantel","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb9005","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.jacc.2012.02.021","article-title":"The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?","volume":"59","author":"Nicholls","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0285","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1172\/JCI200422147","article-title":"Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities","volume":"113","author":"Nickoloff","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000247856","article-title":"Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester","volume":"181","author":"Nieboer","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0295","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0190-9622(89)70071-2","article-title":"Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis","volume":"20","author":"Nieboer","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0300","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/intimm\/5.10.1239","article-title":"Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors","volume":"5","author":"Nomura","year":"1993","journal-title":"Int Immunol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0305","first-page":"643","article-title":"Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing","volume":"25","author":"Nozaki","year":"1987","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0310","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/pr.110.003301","article-title":"International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B)","volume":"63","author":"Offermanns","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0315","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0320","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1172\/JCI112283","article-title":"Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis","volume":"77","author":"Pentland","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0325","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(81)92627-1","article-title":"Is cutaneous flushing prostaglandin mediated?","volume":"1","author":"Phillips","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0330","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1610-0387.2009.07120.x","article-title":"Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis\u2014a retrospective study (FUTURE)","volume":"7","author":"Reich","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/000155500750042907","article-title":"Inflammatory mediators in normal, sensitive and diseased skin types","volume":"80","author":"Reilly","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0340","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev.biochem.70.1.281","article-title":"Regulation of phosphoinositide-specific phospholipase C","volume":"70","author":"Rhee","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0345","doi-asserted-by":"crossref","first-page":"18028","DOI":"10.1074\/jbc.M701866200","article-title":"Nicotinic acid receptor agonists differentially activate downstream effectors","volume":"282","author":"Richman","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0350","first-page":"2347","volume":"27","author":"Rohte","year":"1977","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0355","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clindermatol.2008.07.001","article-title":"Fumaric acid esters","volume":"26","author":"Rostami Yazdi","year":"2008","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0360","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/1523-1747.ep12519287","article-title":"Changes in arachidonic acid metabolism in UV-irradiated hairless mouse skin","volume":"81","author":"Ruzicka","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0365","first-page":"1260","article-title":"Fumars\u00e4ure lindert die Schuppenflechte","volume":"15","author":"Sch\u00e4fer","year":"1984","journal-title":"Selecta"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0370","first-page":"103","volume":"13","author":"Schweckendiek","year":"1959","journal-title":"Med Monatsschr"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0375","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1021\/jm800258p","article-title":"3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice","volume":"51","author":"Semple","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0385","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mce.2010.07.009","article-title":"When simple agonism is not enough: emerging modalities of GPCR ligands","volume":"331","author":"Smith","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0380","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1001\/jama.1937.92780510001008","article-title":"Pellagra successfully treated with nicotinic acid: a case report","volume":"109","author":"Smith","year":"1937","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0390","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0006-291X(03)00342-5","article-title":"Molecular identification of nicotinic acid receptor","volume":"303","author":"Soga","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0395","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1938.02790090004002","article-title":"The use of nicotinic acid in the treatment of pellagra","volume":"110","author":"Spies","year":"1938","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/clpt.1991.104","article-title":"Tolerance to nicotinic acid flushing","volume":"50","author":"Stern","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0405","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2008.08.041","article-title":"The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist","volume":"375","author":"Tang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0926-9959(94)00056-6","article-title":"Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm\u00ae) in psoriasis","volume":"4","author":"Thio","year":"1995","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0415","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2133.1994.tb08589.x","article-title":"Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes","volume":"131","author":"Thio","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0420","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0425","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/1523-1747.ep12535042","article-title":"Noninvasive assessment of local nicotinate pharmacodynamics by photoplethysmography","volume":"80","author":"Tur","year":"1983","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0430","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.smim.2005.05.009","article-title":"Cutaneous dendritic cells","volume":"17","author":"Valladeau","year":"2005","journal-title":"Semin Immunol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0435","first-page":"485","volume":"129","author":"van Dijk","year":"1985","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0440","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2133.2009.09267.x","article-title":"Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study","volume":"162","author":"Wain","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0445","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1172\/JCI36806","article-title":"Beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice","volume":"119","author":"Walters","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0450","doi-asserted-by":"crossref","first-page":"20175","DOI":"10.1016\/S0021-9258(20)80710-8","article-title":"Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor","volume":"268","author":"Watabe","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0455","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0460","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/ATVBAHA.109.201129","article-title":"Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids","volume":"30","author":"Wu","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.06.003_bb0465","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbrc.2005.06.141","article-title":"Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A","volume":"334","author":"Zhang","year":"2005","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T14:39:53Z","timestamp":1642603193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0163725812001210"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.06.003","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}